DEFINE: Switching to Symtuza in HIV patients with weight gain

Phase 4, randomised, open-label trial of tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Janssen Scientific Affairs. Primary endpoints: Percent Change From Baseline in Body Weight at 24 weeks and Percent Change From Baseline in Body Weight: BMI >= 30 Subgroup at 24 weeks. Started Jul 2020; status: completed.